Collegium Pharma (NASDAQ: COLL) reported Q1 EPS of ($0.29), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $74.5 million versus the consensus estimate of $70.82 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.